The polymeric immunoglobulin receptor (pIgR) is important in host defense, transporting antibodies across mucosal epithelial cells. Recent work has shown that, using a protein that binds directly to the pIgR, Streptococcus pneumoniae can co-opt the transcytosis machinery and gain entry into airway epithelial cells.
Streptococcus pneumoniae is an important human pathogen, causing diseases ranging from relatively mild otitis media to potentially fatal sepsis, pneumonia and meningitis [1] . The upper respiratory tracts of many healthy individuals are colonized with non-invasive S. pneumoniae. The balance between colonization and invasion relies on an uneasy truce between the opposing forces of host defense and bacterial virulence factors. The consequences of violating this truce are disastrous to both the host and the unwelcome guests; a massive inflammatory response is highly effective in clearing the pneumococci, but the resultant tissue damage can lead to significant morbidity and mortality for the host.
Secretory antibodies of the immunoglobulin A (IgA) class, together with non-specific defense mechanisms, are gen-erally effective at preventing invasion of upper airway epithelium and blocking access of pneumococci to the bronchi and lungs. These defenses may be inadequate, however, in infants, the elderly and immunocompro-mised individuals. Major pneumococcal virulence factors include the polysaccharide capsule, cell-wall constituents and a variety of bacterial proteins that facilitate adhesion or inhibit host defense mechanisms. Included among these virulence factors are a family of cholinebinding proteins, which are secreted by the pneumococci and anchored to the bacterial cell wall by binding to phosphorylcholine moieties of teichoic and lipoteichoic acid [2] .
A novel aspect of human-pneumococcal relations has recently been revealed by the characterization of the S. pneumoniae choline-binding proteins CbpA and SpsA, which specifically interact with the 'secretory component' of human secretory IgA [3] [4] [5] . These pneumococcal proteins have highly homologous carboxyl termini that include a large choline-binding region and an internal element that is necessary and sufficient for binding secretory component (Figure 1 ). The functions of the divergent amino termini of these proteins are unclear at present.
Independent studies [4, 5] , using different strains of S. pneumoniae, have shown that insertional inactivation of the gene for either CbpA or SpsA causes a total loss of binding to secretory component, suggesting that the proteins may be encoded by allelic forms of a single gene with significant sequence variation among strains. The choline-binding proteins appear to play an important role in S. pneumoniae pathogenesis: recent results [5] have shown that, by binding directly to the polymeric immunoglobulin receptor (pIgR), which transports antibodies across mucosal epithelial cells, CbpA/SpsA allows the invading bacterial cells to co-opt the transcytosis machinery and gain entry into airway epithelial cells.
Polymeric immunoglobulin receptor -defender of the fort
Secretory IgA is the first line of specific immune defense that protects the mucous membranes from inhaled, ingested and sexually transmitted pathogens [6] [7] [8] . Local plasma cells in mucosal tissues secrete predominantly polymeric IgA, which binds to the pIgR on the basolateral surface of mucosal epithelial cells (Figure 2 ) [9] . The pIgR mediates transport of polymeric IgA across polarized epithelial cells, allowing cleavage and release of secretory component, either free or bound covalently to IgA (Figure 3 ). The association with secretory component has been shown to protect secretory IgA antibodies from proteolytic degradation. While pIgR can be internalized from the apical surface of a mucosal epithelial cell and The domain structures of CbpA and SpsA, based on an alignment of the protein sequences of CbpA from strain R6x of S. pneumoniae and SpsA from strain 1 of S. pneumoniae. The proteins are composed of a divergent amino-terminal region (white), a minimal pIgR/secretory component-binding domain of about 105 residues (yellow), a linker region (green), nine or ten choline-binding repeats (blue) and a short carboxy-terminal region (red). transported in retrograde fashion to the basolateral surface, this pathway is clearly less efficient than basolateral-toapical transcytosis.
Protection against potential pathogens can occur at three levels during or following pIgR-mediated transport of polymeric IgA [9, 10] . Firstly, secretory IgA in external secretions acts as an immunological barrier, preventing adherence and invasion of the epithelial layer by microorganisms. Secondly, polymeric IgA can neutralize viruses, and possibly also bacteria, intracellularly during pIgRmediated transcytosis. Finally, pIgR can transport large immune complexes, and probably also microorganisms coated with polymeric IgA, from the basolateral surface of a mucosal epithelial cell to the apical surface, allowing for safe disposal of harmful antigens and potential pathogens.
A notable feature of the pIgR transcytosis pathway is the efficient transport of unoccupied receptors, leading to the release of free secretory component at the apical surface of a mucosal epithelial cell ( Figure 3 ). Human milk, bile and respiratory secretions contain significant levels of free IgA secretory component, suggesting that this by-product of pIgR transcytosis may serve biological functions distinct from its association with IgA [9] . Interestingly, during human fetal development and early infancy, production of pIgR and secretory component precedes that of IgA by several months [11] . The recent findings [3] [4] [5] that the pneumococcal protein CbpA/SpsA interacts specifically with secretory component suggests that free secretory component may also have an important defense role, by blocking adherence of S. pneumoniae to pIgR on surfaces of mucosal epithelial cells.
Zhang et al. [5] found that preincubation of S. pneumoniae with free secretory component prevented subsequent invasion by the bacterial cells of cultured human pharyngeal carcinoma cells. The presence of free IgA secretory component in respiratory secretions and in breast milk may therefore be important in protecting infants who have not yet developed specific IgA antibodies from pneumococcal infections. The pIgR can thus defend the 'fort' against pneumococcal invasion in two ways: by providing a transport mechanism for protective IgA antibodies, and by providing free secretory component to block bacterial adherence.
The polymeric immunoglobulin receptor as a Trojan Horse
The ability of cell surface pIgR to bind pneumococcal CbpA/SpsA is, for both the pathogen and host, a doubleedged sword. The binding of S. pneumoniae CbpA/SpsA to pIgR on the nasopharyngeal epithelium, its preferred niche, presumably provides a mechanism for colonization. Three factors should normally prevent pIgR-mediated internalization of pneumococci: cleavage of pIgR from the apical surface; the relative inefficiency of apical-to-basolateral transcytosis; and the presence of free secretory component and secretory IgA antibodies in the respiratory secretions. But an imbalance in any of these factors, or an overwhelming infection with pneumococci, could tip the scales in favor of invasion.
Zhang et al. [5] have convincingly demonstrated that the production of pIgR by cultured epithelial cells promoted invasion and apical-to-basolateral transcytosis of wild-type, but not CbpA-deficient, S. pneumoniae. Invasion was blocked by antibodies against either CbpA or secretory component, or by free secretory component itself, demonstrating the specificity of the pIgR-CbpA interaction. Furthermore, the enhancement of pIgR production by interferon-γ caused a corresponding increase in pneumococcal invasion. An inflammatory response to pneumococcal infection could therefore actually enhance pIgR-mediated bacterial invasion. The pIgR would thus seem to facilitate pneumococcal invasion, and the in vivo significance of this was tested by measuring the outcome of pneumococcal infection in two models of deficient pIgR transcytosis. Mice deficient in pIgR exhibited decreased nasal colonization by S. pneumoniae relative to wild-type, and mice deficient in the protein tyrosine kinase p62 yes , which is required for normal pIgR transcytosis [12] , showed a delayed onset of bacteremia relative to wild-type. Furthermore, in an earlier study [2] , CbpA-deficient pneumococci were found to colonize the infant rat nasopharynx at a 100-fold lower efficiency than wild-type pneumococci. The mechanisms underlying these in vivo effects are unclear in light of recent evidence [4] that pneumococcal SpsA protein does not bind mouse or rat secretory component or secretory IgA. It is possible, however, that a level of binding below the detection limit of in vitro assays might still be sufficient to mediate in vivo effects. Alternatively, the pIgR transcytosis pathway could be exploited if polymeric IgA were bound to the surface of the pneumococci.
Other results have implicated the pIgR transcytosis pathway in promoting, rather than preventing, invasion by pathogens. Polymeric IgA antibodies have been reported [13, 14] to facilitate entry of Epstein-Barr virus (EBV) into epithelial cells by pIgR-mediated endocytosis, although the outcome of virus internalization -transcytosis or productive infection -depended on the degree of epithelial cell polarization. Other studies [15, 16] demonstrated that EBV could infect pIgR-expressing nasopharyngeal carcinoma cells in the presence, but not in the absence, of EBV-specific polymeric IgA. Furthermore, pIgR protein and EBV RNA were found to be colocalized in biopsies of nasopharyngeal carcinoma.
A recent study [17] found that the level of vaginal disease following infection by type 2 Herpes Simplex Virus is reduced, relative to wild-type, in J-chain-deficient mice, which cannot assemble polymeric immunoglobulins and are therefore deficient in pIgR-mediated transcytosis. The common theme in these viral infections is that virusspecific polymeric IgA appears to act as a 'bridge' between pathogen and pIgR. The recent demonstration [5] of a direct interaction between pneumococcal CbpA/SpsA and pIgR suggests a novel and devious mechanism by which bacteria may use pIgR as a 'Trojan Horse' to invade the unsuspecting epithelial cell.
An evolutionary perspective
From the point of view of S. pneumoniae, the most beneficial outcome of interaction with its host is colonization, not invasion. The bacteria would therefore gain an adaptive advantage by producing a surface protein that can bind to a cell-surface protein expressed at high levels on the host nasopharyngeal epithelium. The pIgR fits this bill nicely, as it is produced at high levels in the upper, but not the lower, respiratory tract. Several observations support the view that the CbpA/SpsA-pIgR interaction is of adaptive significance. Rosenow et al. [2] reported that the level of CbpA was higher in transparent, compared to opaque, variants of S. pneumoniae strain R6x. They suggested that CbpA is subject to phase variation and is a marker for colonization-proficient phase variants of pneumococci. Hammerschmidt et al. [3] found that SpsA is produced by 73% of tested S. pneumoniae clinical isolates that they tested, and is highly conserved between different serotypes.
The hexapeptide motif YRNYPT within the carboxyterminal domain of SpsA that binds pIgR/secretory component was shown to be sufficient, as a hexapeptide, to inhibit the interaction between S. pneumoniae and secretory IgA [4] . The sequence RRNYPT occurs twice in the CbpA sequence, at positions 125 and 287. The latter occurrence is analogous to the location of the motif in SpsA, and the former is in an upstream region, unique to CbpA, that is highly homologous to the pIgR/secretory component-binding domain [5] . The lack of requirement for the amino-terminal domains of CbpA of SpsA for binding to either the pIgR/secretory component or choline suggests that sequence divergence in this region might be permissible and perhaps beneficial from the point of view of evading host immune responses.
The interaction between pIgR/secretory component and pneumococcal CbpA/SpsA appears to be a uniquely human trait. Using several in vitro protein-binding assays, Hammerschmidt et al. [4] demonstrated that SpsA binds to secretory component and secretory IgA from humans, but not rabbits, rats, mice or guinea pigs. Using cell-culture models of adherence and invasion, Zhang et al. [5] showed that CbpA interacts with human, but not rabbit, pIgR. The sequence of pIgR has now been determined for six mammalian and one marsupial species, revealing significant regions of conservation and divergence. Rabbit pIgR is the most diverged in sequence from human pIgR, consistent with the observation that cells producing rabbit pIgR were non-permissive for S. pneumoniae invasion.
The most divergent segment of the pIgR protein among all the species is found within extracellular domains 2 and 3, which can be absent, as a result of alternative splicing, from rabbit pIgR without loss of function [9, 18] . Three amino acid polymorphisms in human pIgR sequence have been identified from protein [19] or mRNA sequences. While the S357G and A562V polymorphisms are conservative and unlikely to alter pIgR function, the L183R polymorphism, which replaces a hydrophobic residue with a basic one, occurs within the highly divergent domain 2. Significantly, mouse, rat and rabbit pIgR, which appear not to bind CbpA/SpsA, differ from human pIgR at this residue. To increase our understanding of the nature of S. pneumoniae adhesion and invasion, it will be important to locate the binding site for CbpA/SpsA on pIgR, and to determine the effects of pIgR polymorphisms on CbpA/SpsA binding.
The future of human-pneumococcal relations
The optimal approach for preventing human disease caused by S. pneumoniae would be the development of a vaccine that prevents both colonization and disease. Current vaccine strategies, including the highly effective polysaccharide-protein conjugate vaccines [20] , have primarily targeted the polysaccharide capsule. A serious limitation of polysaccharide-based vaccines is the high variability of polysaccharide structure among serotypes of S. pneumoniae, more than 80 of which have been identified. A vaccine targeted at the CbpA/SpsA molecule, especially at its conserved domain that binds the pIgR/IgA secretory component, would have the potential to block both colonization and invasion. The identification of a peptide that is capable of blocking S. pneumoniae adhesion has exciting implications for vaccine development. This approach, in conjunction with established polysaccharide conjugate vaccines, holds promise for providing broad spectrum protection against invasive disease caused by S. pneumoniae.
